# Telum Therapeutics S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/telum-therapeutics-s-l

- Industry: Biotechnology
- Headquarters: Spain
- Website: www.telumtherapeutics.com/
- Total disclosed funding: $20M
- Latest round: Series A (Jul 1, 2026)
- Investors on record: 6

## About

Based in Navarra, Sapin, founded in 2019, Telum Therapeutics S.L. operates as a biotechnology company that develops protein-based treatments for drug-resistant bacterial infections using synthetic biology and artificial intelligence. The company was co-founded by Roberto Diez Martinez and Ruben Diez. Currently Subhendu Basu serves as the CEO as of 2026. In July 2026, Telum Therapeutics S.L. raised EUR 18 million in series A funding led by AMR Action Fund, with participation from Inveready Asset Management, Invivo Partners, Center for Technological & Industrial Development, Clave Capital and Sodena. 

The company plaans to use the July 2026 funding to support Phase 1 clinical studies for its lead Acinetobacter baumannii program, generate safety and translational evidence, and advance additional antimicrobial candidates.

## Funding rounds

- Series A, Jul 1, 2026, $20M — Inveready Asset Management, Sodena, Center for Technological & Industrial Development, Invivo Partners, AMR Action Fund, Clave Capital

## Investors

- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Series A
- Sodena (https://capitalatlas.ai/funds/sodena) — Series A
- Center for Technological & Industrial Development (https://capitalatlas.ai/funds/center-for-technological-industrial-development) — Series A
- Invivo Partners (https://capitalatlas.ai/funds/invivo-partners) — Series A
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series A
- Clave Capital — Series A